Mutations in tyrosine kinase receptors (ALK, EGFR, ERBB2, ERBB4, FGFR3, MET, KIT, KDR/VEGFR2) potentially amenable to target therapies were found in 9.2% of cases, with a higher prevalence in GBC (6/26 cases, 23.1%) than in ICC (4/70 cases, 5.7%) and ECC (4/57, 7.0%). This evidence concerns the gene ERBB4 and intrahepatic cholangiocarcinoma.